|
|
 | | | |
- close
- close
- close
- close
Amyris Biotechnologies (AMRS) |
Suggest other news sources for this topic
WIKI ANALYSIS
 |
This company completed an initial public offering (IPO) of its stock in 2010. View articles that reference this company. Recent IPOs: Globe Specialty Metals • LogMeIn • Invesco Mortgage Capital • Medidata • Chemspec |
Amyris Biotechnologies (NASDAQ:AMRS) creates, sells, and distributes renewable products that replace chemicals and fuels made from petroleum. Amyris genetically modifies yeast cells to ferment feedstocks into a series of different target molecules. The company then sells these target molecules to replace additives or fuels which are made from petroleum. The company originally focused on using sugar cane stalks and turned them into farnesene which is key additive in detergents, cosmetics, and transportable fuels among other things. Amyris has continued to diversify both the inputs it can take and the output molecules it can produce. Amyris has pushed to make its products competitive, both in price and effectiveness of replacement, even if they are renewable.[1]
Amyris currently does not have any commercial level efforts in place. It has only established a test facility next to its laboratories in California. The company hopes to expand to commercial distribution levels during 2011 by establishing contracts with sugar cane mills in Brazil. The company has agreed through a letter of intent with a large Brazilian manufacturer to establish a joint venture facility which would turn 10% of their sugar cane into farnesene.[2] The company has also entered into commercialization agreements with large chemical and cosmetic companies such as Procter & Gamble Company (PG).[3]
The company's initial public offering of stock filed on the NASDAQ and went public on the 27 of September 2010. It priced at $16, which was well below the initial price range of $18-$20. The company raised $85M by offering 5.3M shares. The lead underwriter of the deal were J P Morgan Chase (JPM), Morgan Stanley (MS), and Goldman Sachs Group (GS).[4]
Despite not producing at commercial levels, the company has achieved a net revenue for 2009 of $65M. However, due to the high Research & Development costs associated to its developmental stage, it incurred a net loss of $64M.[5]
References
- ↑ AMRS S-1/A 2010 "Our Company" pg 1
- ↑ AMRS S-1/A 2010 "Commercial Production" pg 2
- ↑ AMRS S-1/A 2010 "Commercialization and Distribution" pg 2
- ↑ Renaissance Capital - IPO "Amyris Biotechnologies prices IPO at $16, below the proposed range" 28 Sept 2010
- ↑ AMRS S-1/A 2010 "SUMMARY CONSOLIDATED FINANCIAL DATA" pg 10
| |||||||
